BioCentriq Inc.’s newly constructed GMP manufacturing facility in South Brunswick is officially in business.
The team celebrated the Princeton Corporate Plaza site – which was completed in January but needed to be validated and commissioned – with a ribbon-cutting ceremony Oct. 27.
The facility was designed to accommodate a variety of cell and gene therapy projects. Similar to what’s already in use at BioCentriq’s Newark facility, the new site has two ISO-7 certified clean rooms with separate air handling units.
It also includes quality control and process development laboratories.
“We are thrilled to be opening an additional GMP [good manufacturing practice] manufacturing site as part of BioCentriq’s expansion plan. With this added capacity, BioCentriq can take on more projects to help biotech companies bring their products from bench to market, which is what we do best,” CEO Haro Hartounian said in a statement.
In the announcement, BioCentriq said it’s planning to expand further, with additional manufacturing suites, supporting labs and infrastructure scheduled to open in 2023.
“Right now, there is a massive need for cell and gene therapy CMDOs [contract development manufacturing organizations] with both the appetite and expertise in development and clinical manufacturing of promising allogeneic and autologous cell therapies,” said Amy Lamperti, BioCentriq’s senior vice president of commercialization, adding that the company was “proud to fill that gap.”
Founded in 2019 as a New Jersey Innovation Institute company, BioCentriq designs and develops scalable cell and gene technologies. NJII sold the firm in May to GC Group of South Korea for $73 million.